Scandibio Therapeutics AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://scandibio.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Not Applicable
1 (33.3%)Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
Not Applicable
Not yet recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Combined metabolic activatorsOther: Collagen and maltodextrin
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- ScandiBio Therapeutics AB
- Target Recruit Count
- 845
- Registration Number
- NCT07062198
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ScandiBio Therapeutics AB
- Target Recruit Count
- 100
- Registration Number
- NCT04573153
- Locations
- 🇹🇷
University of Health Sciences Istanbul Ümraniye Training and Research Hospital, Istanbul, Turkey
Metabolic Cofactor Supplementation in Obese Patients with Non-Alcoholic Fatty Liver Disease
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: Metabolic Cofactor Supplementation
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- ScandiBio Therapeutics AB
- Target Recruit Count
- 32
- Registration Number
- NCT04330326
- Locations
- 🇹🇷
Koç University Hospital, Istanbul, Turkey
News
No news found